Program
napazimone
Also written as “KL1333”, “Napazimone” and “KL1333 25 mg”.
Its studies are mostly in Mitochondrial Diseases · MELAS Syndrome · Muscular Diseases, led by 2 companies.
Drug pageNapazimone: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharming Groupits history only | 42 open or running | phase 2since Dec 6, 2022 | Mar 19, 2019 | Oct 2027phase 2 · NCT05650229 |
| Yungjin Pharm. | 10 open or running | phase 1since Feb 5, 2017 | Feb 5, 2017 | none ahead |
Also a collaborator on its studies: ICON.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Yungjin Pharm. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 5, 2017First study: phase 1 study in MELAS SyndromeFirst studyNCT03056209 · 60 enrolled · Korea, Republic of
- Aug 11, 2024Named napazimoneINNProposed as its International Nonproprietary Name in WHO's List 131 · before, KL1333
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Yungjin Pharm. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03056209MELAS Syndrome · Korea, Republic of | 1 | Completed | Apr 16, 2018 | 60 |
How it is read
Names in the registry
- “KL1333”, 3 entries
- “Napazimone”, 1 entry
- “KL1333 25 mg”, 1 entry
- “KL1333 50 mg”, 1 entry
- “KL1333 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Mitochondrial Diseases, 2 studies
- MELAS Syndrome, 2 studies
- Muscular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.